Wall Street analysts expect that Aptinyx Inc (NASDAQ:APTX) will post sales of $1.10 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Aptinyx’s earnings, with estimates ranging from $1.00 million to $1.20 million. The business is expected to report its next earnings results on Tuesday, November 13th.
On average, analysts expect that Aptinyx will report full-year sales of $6.50 million for the current year, with estimates ranging from $6.00 million to $6.99 million. For the next financial year, analysts anticipate that the business will report sales of $4.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that cover Aptinyx.
Aptinyx (NASDAQ:APTX) last released its earnings results on Tuesday, August 14th. The company reported ($1.83) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by ($1.35). The company had revenue of $2.13 million during the quarter, compared to analysts’ expectations of $2.10 million.
Shares of Aptinyx stock traded up $0.01 during trading hours on Monday, reaching $28.20. 605 shares of the company’s stock were exchanged, compared to its average volume of 225,629. Aptinyx has a 52-week low of $17.35 and a 52-week high of $32.25.
Institutional investors have recently modified their holdings of the business. Point72 Hong Kong Ltd acquired a new stake in Aptinyx in the 2nd quarter valued at $134,000. Birchview Capital LP acquired a new position in Aptinyx in the second quarter worth approximately $242,000. TD Asset Management Inc. acquired a new position in Aptinyx in the second quarter worth approximately $253,000. Northern Trust Corp acquired a new position in Aptinyx in the second quarter worth approximately $304,000. Finally, Mutual of America Capital Management LLC acquired a new position in Aptinyx in the second quarter worth approximately $457,000. 60.09% of the stock is currently owned by institutional investors.
Aptinyx Company Profile
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
Read More: Put Option
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.